Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Thursday.

Several other research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Rexahn Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 13th. Seaport Global Securities reaffirmed a “buy” rating and issued a $13.00 target price on shares of Rexahn Pharmaceuticals in a report on Friday, October 6th. HC Wainwright set a $20.00 target price on shares of Rexahn Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, September 11th. Finally, Ifs Securities reaffirmed an “outperform” rating on shares of Rexahn Pharmaceuticals in a report on Monday, August 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $13.85.

TRADEMARK VIOLATION NOTICE: “ValuEngine Upgrades Rexahn Pharmaceuticals, Inc. (RNN) to “Sell”” was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/11/02/valuengine-upgrades-rexahn-pharmaceuticals-inc-rnn-to-sell.html.

Hedge funds have recently made changes to their positions in the business. Sabby Management LLC purchased a new stake in Rexahn Pharmaceuticals in the 2nd quarter worth $706,000. Susquehanna International Group LLP purchased a new stake in Rexahn Pharmaceuticals in the 2nd quarter worth $2,905,000. Finally, Renaissance Technologies LLC lifted its stake in Rexahn Pharmaceuticals by 17.6% in the 1st quarter. Renaissance Technologies LLC now owns 5,758,391 shares of the company’s stock worth $2,937,000 after purchasing an additional 862,000 shares in the last quarter.

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Rexahn Pharmaceuticals (NYSEMKT:RNN)

Receive News & Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.